founders for founders

Group of Houston entrepreneurs creates masterclass for aspiring founders

Four Houston entrepreneurs have teamed up to create a program based on each of their expertise that provides a launch pad for aspiring startup founders. Getty Images

For some aspiring startup founders, the biggest thing holding them back is not knowing where to start. A group of former founders and mentors are teaming up to create that first step.

"A few months ago it struck me that maybe there was a gap in the market between the aspiring entrepreneur," says Steve Jennis, "and the accelerator or incubator program."

Jennis, who's a founder, consultant, and mentor in Houston, tapped a few of his fellow founder-mentors to create Founder's Compass, an online masterclass for people who have a business idea but don't know what to do next. Along with Jennis, founder of JCG and PrismTech, the program was created by Brittany Barreto, founder of Pheramor and Femtech Focus; Leela Madan, founder of Madan Law; and Catherine Brown, founder of ExtraBold Sales.

"We thought that the four of us could put together a masterclass comprising of four modules — each module relates to the skill set that we are individually bringing," Jennis tells InnovationMap. "All together, we're representing a framework for new entrepreneurs to get a kickstart to their business and help them with the next step of their journey — whatever that may be."

The four modules will be presented in virtual, interactive classes lasting three hours each and offered in two different ways each month. Students can register for a two-day option — six hours on a Friday followed by another six hours on a Saturday — or a four-week option — three hours on a weeknight once a week for four weeks.

The four modules will cover the following:

  • Validating your business concept and MVP product-market fit (led by Jennis)
  • Customer development, feedback, and target market definition (led Brown)
  • Protecting your intellectual property and managing your business risk (led by Madan)
  • Engaging with the innovation ecosystem and preparing to fundraise (led by Barreto)
Jennis says the program is not intended to be competitive with accelerators, rather Founder's Compass can act as a feeder into these programs. This is why, Jennis says, the masterclass is set up to be relatively cheap at $100 an hour — or $1,200 for the full program.
"We wanted something that was much more convenient, readily available, and easily affordable, so that's why we settled on the two-day or four-evening format to give people something that they didn't have to think about for months," Jennis says. "We saw an opportunity here — not just to be another accelerator — but to be something for people in the game."

Registration for Founder's Compass is open now for September and October, and participants who sign up before August 1 will receive half off — making the course just $600.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted